4528:TYO
Ono Pharmaceutical Co Ltd
2.352,50 JPY
0,00%
(0,00) 1 zi
6 nov., 15:30:00 GMT+9 · JPY
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru 4528...
Capitalizarea bursieră
1,17 tril.
Volum mediu
2,01 mil.
Volum
0,00
Dividende
3,40 %
Dividende trimestriale
20 JPY
Data ex-dividend
29 sept. 2026
Raportul P/V
14,82
Prețul ridicat pe 52 de săptămâni
2.674 JPY
Prețul redus pe 52 de săptămâni
1.908 JPY
Rezultatul pe acțiune
159 JPY
Acțiuni aflate în circulație
514,12 mil.
Nr. de angajați
4 K
Capitalizarea bursieră
1,17 tril.
Volum mediu
2,01 mil.
Volum
0,00
Dividende
3,40 %
Dividende trimestriale
20 JPY
Data ex-dividend
29 sept. 2026
Raportul P/V
14,82
Prețul ridicat pe 52 de săptămâni
2.674 JPY
Prețul redus pe 52 de săptămâni
1.908 JPY
Rezultatul pe acțiune
159 JPY
Acțiuni aflate în circulație
514,12 mil.
Nr. de angajați
4 K
Subiecte de știri
Din surse web și de la parteneri de știri
Investor's Business Daily
·
acum 2 ore
Dow Jones Futures Loom For Damaged Market; Nvidia Probes Huang Spying Case
www.foreignpolicyjournal.com
·
acum 5 minute
Rising Rates Cleave AI Infrastructure Stocks (NASDAQ: CRWV, NBIS, MSFT, MU) Into Winners And Losers
Yahoo Finance
·
acum 39 de minute
Forget the High-Beta Hype: 5 ‘Sleep Well at Night’ Stocks to Buy Now
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Despre Ono Pharmaceutical Co Ltd
Director executivGyo Sagara | Gyo Sagara
Angajați4,21 K
Înființată la1717
SediuOsaka, Prefectura Osaka, Japonia
DomeniuHealth Care
Domeniu de activitate-
Siteono-pharma.com